Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market
December 17, 2020 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative...
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering
December 08, 2020 21:45 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 13, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
November 10, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
October 19, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020
October 07, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020
September 21, 2020 18:09 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
September 17, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19
September 01, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020
August 26, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...